Australia markets closed

PTC Therapeutics, Inc. (BH3.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
31.00-0.40 (-1.27%)
At close: 08:05AM CEST
Currency in EUR

Valuation measures4

Market cap (intra-day) 2.41B
Enterprise value 1.97B
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)2.74
Price/book (mrq)N/A
Enterprise value/revenue 2.13
Enterprise value/EBITDA -7.77

Trading information

Stock price history

Beta (5Y monthly) 0.67
52-week change 3-37.20%
S&P500 52-week change 322.43%
52-week high 354.50
52-week low 316.40
50-day moving average 325.78
200-day moving average 325.66

Share statistics

Avg vol (3-month) 3N/A
Avg vol (10-day) 3N/A
Shares outstanding 576.7M
Implied shares outstanding 682.98M
Float 856.57M
% held by insiders 12.37%
% held by institutions 1112.57%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Currency in USD.

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin -62.45%
Operating margin (ttm)-21.68%

Management effectiveness

Return on assets (ttm)-10.29%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)927.56M
Revenue per share (ttm)12.28
Quarterly revenue growth (yoy)-4.70%
Gross profit (ttm)N/A
EBITDA -30.58M
Net income avi to common (ttm)-579.22M
Diluted EPS (ttm)-7.17
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)890.9M
Total cash per share (mrq)11.62
Total debt (mrq)2.26B
Total debt/equity (mrq)N/A
Current ratio (mrq)2.03
Book value per share (mrq)-11.66

Cash flow statement

Operating cash flow (ttm)-58.17M
Levered free cash flow (ttm)7.58M